{"id":"cmab","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"cMAB works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and allowing for an enhanced immune response against cancer cells.","oneSentence":"cMAB is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:29.079Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT05974774","phase":"PHASE3","title":"Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-05-23","conditions":"Prostate Cancer","enrollment":1600},{"nctId":"NCT02504294","phase":"PHASE3","title":"A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-07-13","conditions":"Chronic Kidney Disease (CKD)","enrollment":432},{"nctId":"NCT01836653","phase":"PHASE2","title":"Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases","status":"COMPLETED","sponsor":"EPS Corporation","startDate":"2013-05","conditions":"Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer","enrollment":122},{"nctId":"NCT01834014","phase":"NA","title":"Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases","status":"COMPLETED","sponsor":"EPS Corporation","startDate":"2013-05","conditions":"Liver Metastasis, Colorectal Cancer","enrollment":110},{"nctId":"NCT02515734","phase":"PHASE2","title":"A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab","status":"UNKNOWN","sponsor":"Japan Clinical Cancer Research Organization","startDate":"2015-08","conditions":"Colorectal Cancer","enrollment":360},{"nctId":"NCT00255268","phase":"PHASE4","title":"CMAB vs IMAB in Metastatic Prostate Cancer","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2004-08","conditions":"Metastatic Prostate Cancer","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":191,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["continuous maximum androgen blockade"],"phase":"phase_3","status":"active","brandName":"cMAB","genericName":"cMAB","companyName":"European Organisation for Research and Treatment of Cancer - EORTC","companyId":"european-organisation-for-research-and-treatment-of-cancer-eortc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"cMAB is a monoclonal antibody targeting the PD-1 receptor. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}